On Monday, Gilead Science announced the cost of remdesivir, the first approved treatment for COVID-19. The drug doesn’t improve a patient’s chances of surviving — at best, it speeds up recovery and lowers the need for hospitalization from fifteen to eleven days, according to a study from the National Institute of Allergy and Infectious Diseases.

While not a miracle cure, Gilead’s pricing would lead you to believe it was. To receive the required six treatments of the drug, private insurance companies will be charged $3,120 — a healthy margin for a medication whose total course of treatment costs $10 to produce. Gilead’s argument is that the reduction in hospital care provides a cost savings that justifies the price.

That price is reserved for American patients with private health insurance, Medicaid, or Medicare, however. In other developed countries, their health care systems will pay 25 percent less for remdesivir. (The same discounted price is also being applied to US government agencies, specifically VA hospitals and the Department of Defense, that directly purchase prescription drugs.)